- 457 adults participated in the trial across 33 US sites.
- Cyclobenzaprine 5.6 mg reduced pain more than placebo at week 14.
- Significant improvements in sleep and fatigue.
- Efficacy measured using various patient-reported outcomes.
- 58.9% of cyclobenzaprine patients experienced TEAEs, mostly mild.
Source: Pain Medicine
